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1. Introduction
Injuries affecting either the peripheral or the central nervous system (PNS, CNS) leads to
neuropathic pain characterized by spontaneous pain and distortion or exaggeration of pain
sensation. Peripheral nerve pathologies are considered generally easier to treat compared to
those affecting the CNS, however peripheral neuropathies still remain a challenge to thera‐
peutic treatment.
Animal models such as denervation/neuroma formation [1], chronic constriction injury (CCI)
by loose ligatures around the sciatic nerve [2], partial tight ligation of the sciatic nerve trunk
(partial sciatic nerve ligation, PNL) [3]; tight ligature of L5 and L6 spinal nerves (spinal nerve
ligation, SNL) [4]; section of one or two components of the sciatic nerve (spared nerve injury,
SNI) [5]; streptozocin induced diabetic neuropathy [6] and peripheral neuropathy induced by
vincristine or by anti-retroviral nucleoside analogue AIDS therapy drugs [7, 8] have been
designed to mimic different neuropathic syndromes and reproduce in laboratory neuropathic
pain main symptoms. Indeed all the mentioned neuropathic pain models show increased
responses to thermal or mechanical nociceptive stimulation (hyperalgesia), hypersensitivity
to innocuous tactile or cold stimuli (allodynia) which lead to withdrawal behaviour.
2. Peripheral pathophysiology change mechanisms
A large body of studies has been accumulated during the last two decades to characterize and
clarify mechanisms at the base of neuropathic pain development and maintenance. Peripheral
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nerve injury causes axon and myelin sheath degradation associated with macrophage,
neutrophil and T cell infiltrations [9, 10].
The release of proinflammatory cytokines (interleukins, tumor necrosis factor-α) and media‐
tors (bradykinins and prostaglandins) and growth factors (nerve growth factor) leads to
peripheral sensitization and hypersensitivity to innocuous and noxious stimuli [11, 12].
Bradykinins and prostaglandins potentiates, among other things, the activity of transient
receptor potential vanilloid type 1 (TRPV1) channel, highly expressed on Aδ and C fibers,
whose activity and expression is potentiated in neuropathic pain models [13-16]. Neuropathic
pain causes also over-expression of voltage gated sodium channels and increases sodium
currents leading to spontaneous discharges of Aδ and C fibers [17-19]. Peripheral sensitization
is also associated with increased voltage gated Ca2+ channels [20, 21]. Increased intracellular
Ca2+ elevates substance P (SP) and glutamate release thus exacerbating pain transmission.
3. Spinal pathophysiology change mechanisms
Beside the peripheral mechanisms which are responsible of the immediate damage-induced
changes in pain transmission, several spinal cellular and molecular changes are involved in
the development of the neuropathic pain symptoms, such as thermal and mechanical hyper‐
algesia and tactile allodynia. Although first being thought as a disease of purely neuronal
nature, several pre-clinical studies indicate that the mechanisms at the basis of the develop‐
ment and maintenance of neuropathic pain involve substantial contributions from the non-
neuronal cells of both the PNS and CNS [22]. After peripheral nerve injury, microglia in the
normal conditions (usually defined ‘‘resting’’ microglia) in the spinal dorsal horn proliferate
and change their phenotype to an “activated” state through a series of cellular and molecular
changes.
Microglia shift their phenotype to the hypertrophic “activated” form following altered
expression of several molecules including cell surface receptors, intracellular signalling
molecules and diffusible factors. The activation process consists of distinct cellular functions
aimed at repairing damaged neural cells and eliminating debris from the damaged area [23].
Damaged cells release chemo-attractant molecules that both increase the motility (i.e. chemo‐
kinesis) and stimulate the migration (i.e. chemotaxis) of microglia, the combination of which
recruits the microglia much closer to the damaged cells [24]. It has been shown that microglia
activation in the spinal cord can be promoted by sciatic nerve ligation [25], spinal nerve ligation
[26], sciatic nerve inflammation [27], traumatic nerve transection [28] and autoimmune
diseases such as autoimmune encephalomyelitis and neuritis (EAE, EAN) [29, 30].
Once microglia become activated, they can exert both proinflammatory or anti-inflammatory/
neuroprotective functions depending on the combination of the stimulation of several
receptors and the expression of specific genes [31]. Thus, the activation of microglia following
a peripheral injury can be considered as an adaptation to tissue stress and malfunction [32]
that contribute to the development and subsequent maintenance of chronic pain [33, 34].
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Spinal microglia respond quickly to injury, up-regulating cell surface proteins and increasing
synthesis and the release of inflammatory mediators, including cytokines and proteases that
can sensitize neurons, thereby establishing positive feedback which helps to facilitate noci‐
ceptive signalling [35]. Accordingly, the inhibition of microglia targets can reduce hypersen‐
sitivity in neuropathic pain states.
The signals responsible for neuron-microglia and/or astrocyte communication are being
extensively investigated since they may represent new targets for chronic pain management.
The first candidates are substances released by activated nociceptive primary afferent fibers,
such as glutamate and SP, which are capable to activate microglia [36, 37]. Glutamate activates
microglia by stimulating NMDA receptors [37], although other mechanisms involving
metabotropic glutamate receptors (mGluRs) cannot be ruled out since it has been shown that
mGluRs are expressed on microglial cells [38, 39]. SP acts mostly by activating microglia
neurokinin-1 (NK1) receptors. Many mechanisms have been proposed for neuron-microglia
crosstalk. Among these, the fractalkine (FKN, CX3CL1), a member of CX3C class of chemokines
and its receptor CX3CR1 have been extensively investigated [39]. FKN is constitutively
expressed by spinal cord and sensory neurons in the dorsal root ganglia (DRGs) [40-42], while
CX3CR1 is exclusively expressed by microglia cells and, after peripheral nerve injury it is
largely up-regulated in activated microglia [41]. FKN produces nociceptive behaviour by
activating CX3CR1 on microglia and p38 mitogen-activated protein kinase (MAPK)-mediated
pathways [42, 43]. A pathway for the cleavage of FKN from the membrane of neurons, has
been elegantly demonstrated [42]. Briefly, neuronal FKN is cleaved by Cathepsin S (CatS), a
proteolitic enzyme which is synthesized and released by activated microglia. Despite the
CX3CL1/CX3CR1 pathway represents a pro-nociceptive non adaptive process, seems to
perform also a neuro-protective action in neurodegenerative diseases [44].
Another chemokine implicated in neuron-glia communication is the chemokine (C-C motif)
ligand 2 (CCL2, MCP-1), which is de novo expressed by sensory neurons as early as a day after
peripheral injury [44]. Once released, CCL2 activates microglia via interaction with CCR2
receptors, and, accordingly, mice lacking CCR2 receptors display a reduction in nerve injury-
induced tactile allodynia [45]. The action of the monocyte chemoattractant protein 1 (MCP-1)
at the spinal level has also been demonstrated by the intrathecal administration of an MCP-1
neutralizing antibody, which proved able to inhibit neuropathic pain symptoms [44]. Another
important candidate for neuronal-microglial cross-talk is ATP, that is produced by neurons as
well as by glial cells. ATP exerts its effect on microglia by activating the purinergic ionotropic
P2X4 and P2X7, as well as the metabotropic P2Y6 and P2Y12, receptors which are up and/or
down-regulated in several conditions [46]. The stimulation of the P2X4 channel seems to be
involved in the development of neuropathic pain by inducing the release of brain derived
neurotrophic factor (BDNF) [47, 48]. In particular, this mechanism is believed to be responsible
of the appearance of the tactile allodynia by inverting the ionic gradient of the GABAergic
interneurons following the down-regulation of the KKC2 calcium transporter [47]. P2X4
receptor activation occurs earlier than that of P2X7 channel due to the greater affinity of ATP
to bind to P2X4 receptor. Indeed, P2X7 is involved in the maintenance of microglial activation.
The P2X7 receptor appears to be a functionally unique ionotropic receptor among the P2X
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receptor family since its activation is able to stimulate the release of the pro-inflammatory
cytokine interleukin-1β (IL-1β) [49], as well as a variety of other pro-inflammatory cytokines.
Recent studies have revealed that P2Y12R is also crucial in neuropathic pain induction and
maintenance. It has been found that the expression of P2Y12R mRNA and protein are markedly
enhanced in the spinal cord ipsilaterally to spinal nerve injury [50] or to sciatic nerve partial
ligation [51]. The cellular location of this receptor in the spinal cord was highly restricted to
microglia and recently has been proposed to be involved in the motility of microglial cell bodies
and processes [52]. It is therefore possible that P2Y12R activity in microglia affects their ability
to extend the branched processes toward neighbouring neurons of the pain matrix, which, in
turn, may interfere with microglia-neuron communications. Recent data suggest that the
metabotropic adenosine receptor A2A is also involved in the microglia process retraction
occurring during microglia activation [53]. The up-regulation of Gs protein-coupled adenosine
A2A receptor on activated microglia seems to occur concomitantly to down regulation of Gi-
protein coupled P2Y12 receptor [53].
4. Supraspinal pathophysiology change mechanisms
Descending pain modulatory system undergoes morpho-functional changes following PNS
or CNS injury contributing to neuropathic pain development and maintenance [54-56]. The
pain modulatory centers include brainstem areas such as periacqueductal gray (PAG), locus
cœreuleus (LC) and rostral ventromedial-medulla (RVM). PAG is recognised as a major source
of pain inhibitory control: its activation produces hypoalgesia by inhibiting nociceptive
sensory processing within the dorsal horn of the spinal cord [57, 58]. PAG-induced analgesia
is produced through the activation of RVM consisting of the raphe magnus and its adjacent
reticular nuclei. Different pain responding cell populations are found in RVM: ON, OFF and
neutral cells. These cells show different reactions to nociceptive stimuli such as excitation,
inhibition or irresponsiveness, respectively [59, 60]. Apart from their well-documented role in
anti-nociception, PAG and RVM mediate also a descending facilitation [61, 62]. Indeed, a shift
in the balance between RVM “pronociceptive” ON cells versus “antinociceptive” OFF cell
activity has been found in neuropathic pain conditions. The ongoing firing of RVM ON cells
was found significantly increased whereas the spontaneous activity of the OFF cells appeared
decreased 7 days after neuropathic pain induction [60, 63]. A functional shift between ON and
OFF cell activity such that ON cell activity predominates over that of the OFF may be respon‐
sible of the facilitatory influence of the RVM on spinal neurons leading to neuropathic
hypersensitivity [64-66, 16, 67]. Moreover, a contribute of serotonergic neurons, considered a
subset of neutral cells, in nociceptive modulation has been evidenced in abnormal pain states
[68]. Thus, changes in RVM cell activity may be considered a sort of sensitization of RVM
neurons during neuropathic pain [69, 70] as consequence of altered peripheral inputs associ‐
ated with spinal processing [71]. Alternatively, RVM cell activity changes may reflect a
different control exerted from the upstream PAG projections. Indeed, a complex morpho-
functional reorganization has been observed within the PAG after neuropathic pain induction.
A decrease in the potency of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrro‐
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lo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanonemesylate (WIN 55,212-2), a
cannabinoid receptor agonist, locally microinjected into the ventrolateral (VL) PAG, has been
recently evidenced in neuropathic rats. Seven days after the CCI of the sciatic nerve WIN
55,212-2 produced antinociception and inhibited the activity of the ON cells while increased
those one of the OFF cells (as centrally acting analgesic drugs are expected to do) at doses
twofold higher than in control rats [67]. Moreover, the expression of cannabinoid type 1 (CB1)
receptor, the CB1 receptor associated Gαi3 and the cannabinoid receptor interacting 1a (CRIP
1a) proteins and the endocannabinoid synthesising enzyme NAPE-PLD proved to be de‐
creased in CCI rats [67]. Thus a down regulation of the endocannabinoid system within the
VL PAG, possibly due to endocannabinoid increase in neuropathic pain state [72], may lead
to an enhancement in pain responses through an altered control of PAG-RVM circuitry on
spinal nociceptive neurons. A hyperactivity of serotonergic neurons and an increase in
endocannabinoids was also observed in CCI animals in dorsal raphe (DR), an area which lies
just ventrally and shows similar morphological properties to the PAG [73]. DR phenotypic
changes during neuropathic pain may have also relevance for the affective component of
chronic pain. Another supraspinal circuitry being involved in to the emotional-affective
aspects of pain is the basolateral amygdala (BLA)-medial prefrontal cortex (mPFC) pathway.
Pyramidal neurons of mPFC respond to BLA electrical stimulation or hind-paw pressoceptive
stimulation with an inhibitory [BLA→mPFC(-)] or excitatory [BLA→mPFC(+)] response [74].
These neurons show a phenotypic rearrangement in SNI-induced mono-neuropathy in the rat,
suggesting that the mPFC may undergo profound reorganization in chronic pain conditions
[75]. Neuropathic pain can shift the balance between excitatory and inhibitory responses in
the BLA→mPFC pathway, resulting in a net increase in the excitatory influence that the BLA
exerts over the prelimbic/infralimbic (PL/IL) neuron population of the mPFC [76-80]. These
functional changes appeared concomitantly with an increase in glutamate levels, as well as an
up-regulation of fatty acid amide hydrolase (FAAH) enzyme and TRPV1 channels in the
PL/IL cortex of SNI rats [75]. Overexpression of several caspases such as caspase-3 and 1,
upregulation of glutamate AMPA receptors in microglia, IL-1β and IL-1 receptor-1, TRPV1
and vesicular glutamate transporter 1 (VGluT1) in glutamatergic neurons were also observed
7 days after SNI in mice. Of these alterations, only those in astrocytes persisted in SNI
TPRV1(-/-) mice. SNI triggers both TRPV1-dependent and independent glutamate- and
caspase-mediated cross-talk among IL-PL cortex neurons and glia, which either participates
or counteracts pain processing. Alterations in endovanilloid system associated with peripheral
nerve injury may suggest that therapies able to normalize endovanilloid transmission or
blocking caspase activation may prove useful in ameliorating symptoms and central sequelae
associated with neuropathic pain [80, 75]. Within the VL PAG the expression of pronociceptive
mediator targets such as the prostaglandin EP1 receptor, whose activation has pain facilitatory
role, proved to be reduced 7 days after neuropathic pain induction by SNI. However, its
blockade and stimulation was still able to inhibit/facilitate pain responses and the ON and OFF
cell activity, as they did in control animals. The major expression of EP1 receptor was found
on GABAergic neurons consistently with an EP1 receptor blockade-induced disinhibition of
the antinociceptive descending pathway at VL PAG level and behavioural antinociception [16].
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5. Cannabinoids and peripheral neuropathy
The discovery and characterization of cannabinoid receptors (CBRs) in the late eighties [81,
82] and the subsequent isolation of endogenous ligands, first of all the arachidonoylethanola‐
mide (AEA) [83], established the existence of a proper endocannabinoid neuromodulatory
system. Cannabinoids include the components of the cannabis plant (Cannabis sativa L.), the
endogenous cannabinoids (endocannabinoids), and several synthetic cannabinoid ligands.
The cannabinoid system is involved in several human physiological functions as testified by
the fact that cannabis intake affects important aspects of behaviour such as short-term memory,
panic reactions, motor coordination, food-intake and pain perception [84, 85]. More than 70
psychoactive compounds have been identified in cannabis, among which Δ9-tetrahydrocan‐
nabinol (THC) accounting for most of the psychological and physical effects. Cannabinoids
exert their effects through the activation of two G protein-coupled receptors identified as the
cannabinoid CB1 and CB2. Their activation is associated with inhibition of adenylate cyclase
and the stimulation of mitogen-activated protein kinase (MAPK). Moreover, CB1 receptor
activation modulates calcium or potassium conductance properties linked to the reduction of
neuronal excitability and neurotransmitter release [86]. CB1 receptor is wide expressed in the
brain, including neuroanatomical regions subserving transmission and modulation of pain
signals, such as the PAG, the RVM and the dorsal horn of the spinal cord [87, 88]. CB2 is found
manly in the peripheral immune system. It is expressed on T and B cells, macrophages, natural
killer and monocytes, however recent studies suggest its expression on neurons at dorsal root
ganglia level and at central level within spinal cord, specifically on glia, microglia and neurons
[89, 28]. Pharmacological evidence also support the existence of non–CB1/CB2 receptor-
mediated cannabinoid effects [90] and different investigations have been identified possible
targets in the orphan G protein–coupled receptor GPR55 [91], transient receptor potential
vanilloid type-1 (TRPV1) channel [92] or peroxisome proliferator-activated receptors (PPARs)
[93]. The endocannabinoids such as AEA, arachidonoylglycerol (2-AG) and N-arachidonoyl‐
dopamine (NADA) are lipid compounds produced on demand by the cleavage of membrane
phospholipid precursors, released from cells immediately after their production and degraded
by specific enzymatic system. AEA is synthesized from enzymatic cleavage of N-arachidonoyl
phosphatidylethanolamine (NAPE) by a specific phospholipase D (NAPE-PLD). It shows
higher affinity for CB (Ki [CB1 vs CB2] = 89 vs 371 nM) and can also activate ionotropic TRPV1
receptors as endovanilloids. Biological inactivation of anandamide occurs through a rapid
uptake followed by intracellular hydrolysis mediated by FAAH.
2-AG, which is more abundant than anandamide in the brain binds to CB1 and CB2 with a
lower affinity than anandamide, but behaves like a full agonist since it shows higher intrinsic
activity [94]. 2-AG is synthesized by the enzyme diacylglycerol lipase (DGL-α) in a Ca2+-
dependent pathway [95]. Other alternative mechanisms of 2-AG synthesis have also been
proposed [96]. Biological inactivation occurs through uptake followed by hydrolysis mediated
by the enzyme monoacylglycerol lipase (MGL). Other enzymes have been indicated for 2-AG
metabolism, including cyclooxygenases (COXs), lipooxygenases (LOXs) and FAAH [97, 98].
The first evidence of the analgesic properties of cannabis was observed in 1899 by Dixon [99].
Crucial studies on cannabinoid-induced antinociception by Bicher and Mechoulam (1968)
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[100] and Kosersky [101] confirmed the ability of cannabinoids to inhibit acute and inflam‐
matory and nerve injury–induced pain. Cannabinoids seem to be useful in alleviating neuro‐
pathic pain symptoms after prolonged treatments [102], unlike opioids, which show only
limited effectiveness [103, 104]. The activation of the CB receptors by synthetic agonists, or
pharmacological elevation of endocannabinoid levels, suppresses hyperalgesia and allodynia
in animal models of neuropathic pain. Local administration of exogenous AEA or 2-AG
significant decreases the hyperalgesia in formalin test or in the PNL [105, 106]. Systemic FAAH
inhibitor (URB597, AA-5-HT, OL-135) administration or the inhibition of endocannabinoid
uptake with AM404 produce antinociceptive effects in CCI [107] or PNL models [3] which are
mainly CB1 receptor-mediated. It is also important to highlight that inhibitors of FAAH elevate
levels of fatty-acid amides that do not bind to CB receptors (e.g. palmitoylethanolamine). Thus,
the contribute of non-cannabinoid receptor mechanisms of action in the in vivo pharmacolog‐
ical effects of FAAH and MGL inhibitors must also be considered. Direct evidence for supra‐
spinal sites of cannabinoid analgesic action was derived from the observation that
administration of cannabinoids compounds straight into the brain induces antinociception.
Martin et al. (1999) [108] demonstrated that WIN55,212-2 produced antinociception in the tail-
flick test when injected into different brain regions including subnuclei of the amygdala,
thalamus, PAG and RVM.
In addition, as previously briefly described, WIN55,212-2 microinjection into the PAG
suppressed the sciatic nerve constriction-induced allodynia and modulated RVM cells activity
[67]. Similar effects have been shown by intra-PAG injection of a FAAH inhibitor URB597
which elevates endocannabinoid levels and reduces the thermal nociception via activation of
CB1 and TRPV1 receptor mechanisms [109]. Moreover, Giordano et al. (2011) [80] have shown
that acute intra-pre-limbic/infra-limbic cortex microinjection of N-arachidonoyl-serotonin
(AA-5-HT), a hybrid FAAH inhibitor and TPRV1 channel antagonist, transiently decreased
the allodynia and modulates the changes occurring on cortex pyramidal neurons induced by
SNI model.
In the complex scenario of neuropathic pain, which also involves non-neuronal pathways, such
as microglial cell-induced synaptic plasticity, the endocannabinoid system may also represent
target to exploite for modulating microglia-neuron communication. Several studies have
focused on CB2 receptor activation in different neuropathic pain models [110, 28, 111, 112].
Such  studies  have  highlighted  the  role  of  CB2  receptor  in  the  modulation  of  immune
response involved in the development of neuropathic pain. CB2 receptor activation exerts
antiallodynic and antihyperalgesic effects by modulating microglia responses. In particu‐
lar,  CB2 receptor  stimulation induced an analgesic  effect  in  SNI mice associated with a
reduction in the pro-inflammatory (IFN-γ and IL-1β) and an enhancement in anti-inflam‐
matory (IL-10) mediators within the spinal cord [28]. Beside the analgesic effect, cannabis
intake can impair cognitive and performance tasks,  such as memory and learning [113].
Activation of central CB1 receptors lead to a combination of stimulatory and depressant
effects [114]. Other effects including catalepsy, motor deficits and thermal imbalance have
been  observed  after  administration  of  centrally  acting  cannabinoids  [115]  These  effects,
mainly associated with activation of central CB1 receptors, deeply limit the clinical use of
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cannabinoids  for  the  treatment  of  chronic  pain  states.  The  synthesis  of  CB2  receptor-
selective agonists which lack of the majority of central side effects and produce antinocicep‐
tive effects represent an interesting pharmacological tool [116].
Cannabinoids can counteract pain in both physiological and pathological conditions. CB1Rs
and CB2Rs are both overexpressed during inflammation and neuropathic pain. In this context,
selective activation of peripheral CB1 or CB2 receptor by cannabinoid agents which do not
penetrate the blood brain barriers or the enhancement of the endocannabinoid levels can be a
promising therapeutic approach that avoid the side effects associated with central CB1 receptor
activation. Finally the isolation of non psychotropic compounds of Cannabis Sativa, such as
cannabidiol or cannabichromene, which show antinociceptive properties in physiological
[117] and pathological [118] pain conditions, could represent an alternative tool in pain
management.
6. Stem cell treatment for peripheral neuropathy
Management of peripheral neuropathy in affected patients could be tailored to individual
requirements, for instance the presence of other co-morbidities could influence the therapy.
Damaged peripheral nerves demonstrate some potential to regenerate, however, complete
functional recovery is infrequent. Novel approaches are required in the clinical management
of peripheral nerve injuries since the current surgical techniques result in deficient sensory
recovery [119].
Nowadays, neuropathy research is focusing on newer cellular and molecular approaches, such
as stem cell therapy. Preclinical studies indicate that stem cell therapy represents the great
promise for the future of molecular and regenerative medicine, including tissue regeneration.
In peripheral neuropathy, stem cells could act in several ways: i) improving the intrinsic
regenerative capacity of injured nerves; ii) inhibiting pathogenic immune responses both in
the periphery and inside the central nervous system; iii) releasing neuroprotective and anti-
inflammatory molecules thus favouring tissue repair.
In the last years, it has been demonstrated that stem cells are neuroprotective in a variety of
nervous system injury models [120]. Briefly, stem cells have been found in all multi-cellular
organisms, they are able to divide and differentiate into diverse specialized cell types. In
addition, stem cells self-renew themselves to produce more stem cells. Indeed, in principle,
their extraordinary properties are the self-renewal (the ability to perform indefinite cell
division cycles while maintaining the undifferentiated state) and the multipotency (the
capacity to differentiate into specialized cell types). The availability of multiple stem cell types
provides both the opportunity and a reasoned approach for treating several, otherwise
untreatable, human diseases [121].
As  neurodegenerative  disease,  also  peripheral  neuropathy  could  benefit  by  stem  cell
therapy.  This  cell-  based treatment  opportunity  represents  a  non-surgical  approaches  to
enhance nerve recovery and re-innervation processes [122, 123]. Indeed, stem cell implan‐
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tation  appears  as  a  possible  curative  treatment  having  the  stem  cells  the  ability  to
incorporate into the site of a lesion, differentiate, and to improve locomotor recovery [124].
Stem  cell  beneficial  effects  are  due  to  their  properties,  as  self-renewal  ability  with  the
capacity to generate more identical stem cells; the capacity to give rise to more differenti‐
ated  cells;  the  capacity  to  produce  neuroprotective  and  anti-inflammatory  molecules
(paracrine regulatory functions) [121].
The ideal  stem cell  source  for  peripheral  neuropathy repair  should be  easily  accessible,
involve  non-invasive  harvesting,  be  rapidly  expandable  in  in  vitro  culture,  be  able  to
survive and integrate within the host nerve tissue [125]. Mesenchymal stem cells (MSCs)
represent a promising therapeutic approach in nerve tissue engineering [126]. These cells
are a population of progenitor cells of mesodermal origin found in the bone marrow of
adults, giving rise to skeletal muscle cells, blood, adipose tissue, vascular and urogenital
systems, and to connective tissues throughout the body [127]. This type of stem cells yields
most  prominent  results  in peripheral  nerve re-generation.  In addition,  MSCs have great
potential  as therapeutic agents since they are easy to isolate and can be expanded from
patients  without  serious  ethical  and  technical  problems  [128].  MSC  treatment  into  a
polycaprolactone  nerve  guide  was  able  to  improve  re-innervation  and  activity  in  mice
undergone  to  nerve  transection  [129].  Interestingly,  some  transplanted  stem  cells  as‐
sumed a Schwann-cell-like phenotype.
In a murine model of sciatic nerve crush injury, intravenous administration of adipose-derived
MSC (ASC) significantly accelerated the functional recovery [126]. Mice showed significant
improvement in fiber sprouting and the reduction of inflammatory infiltrates. The authors
proposed that ASC-mediated positive effects were due to the production of in situ molecules,
which, directly or indirectly through a cross-talk with local glia cells, could modulate the local
environment with the down-regulation of inflammation and the promotion of axonal regen‐
eration. Peripheral neuropathy is a dramatic symptom in Krabbe disease [130]. Hematopoietic
stem cell (HSC) transplantation proved effective in slow the progression of this disease. HSCs
were able to achieve improvement in peripheral nerve conduction abnormalities in Krabbe
patients, suggesting remyelination of the nerves [131]. Diabetic neuropathy is the most
common complication of diabetes, frequently leads to foot ulcers and may progress to limb
amputations [132].
It has been proposed that autologous transplantation of bone marrow-derived mononuclear
cells (BM-MNCs) could be a novel strategy for the treatment of painful diabetic neuropathy
[133]. Indeed, transplantation of BM-MNCs is able to alleviate neuropathic pain in the early
stage of streptozotocin-induced diabetic rats. The BM-MNC transplantation significantly
ameliorated mechanical hyperalgesia and cold allodynia. Diabetic neuropathy is attracting
most research strategies. Several clinical trials have been performed on the use of stem cells
for the treatment of human peripheral diabetic neuropathy (www.clinicaltrials.gov). Induced
pluripotent stem (iPS) cell technology has enormous potentials to advance medical therapy by
personalizing regenerative medicine [134]. iPS cells offer great potentials as a future tool also
for the treatment of peripheral neuropathy. Cell incorporation into conduit repair of peripheral
nerves demonstrates experimental promise as a novel intervention. Tissue-engineered bio-
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absorbable nerve conduits coated with iPS cell-derived neurospheres were able to repair
peripheral nerve gaps in mice [135].
Achieving peripheral nerve regeneration, axonal regeneration and re-myelination with stem
cells is a challenging research goal. This process is very complex, with Wallerian degeneration
being the most elementary reaction and Schwann cells playing an important role. An emerging
solution to improve upon this intrinsic regenerative capacity is to supplement injured nerves
with stem cells [136]. Stem cells effectiveness in the treatment of peripheral nerve injury may
lie in their ability to differentiate into Schwann cells, secrete neurotrophic factors, and assist
in myelin formation [137, 136]. This strategy of introduction autologous stem cells directly into
the site of a nerve injury represents a promising therapy. Skin-derived precursor cells (SKPs)
were successfully transplanted in the sciatic nerve of Lewis rats bridged by a freeze-thawed
nerve graft.
The cells were able to improve nerve re-generation, probably their effect was due to the ability
to secrete bioactive neurotrophins [138]. Another stem cell type, the multipotent hair follicle
stem cells, could provide a potential accessible, autologous source of stem cells for regeneration
therapy of damaged nerves [139]. More recently, in an interesting study, Amoh et al. trans‐
planted hair follicle stem cells around the impinged sciatic nerve of the mice. The cells
differentiated into glia fibrillary acidic protein-positive Schwann cells, promoting the recovery
of pre-existing axons. Authors reported that the regenerated sciatic nerve was functionally
recovered [140]. These hair follicle stem cells could differentiate into several cell types, i.e.
neurons, glia, keratinocytes, smooth muscle cells and melanocytes. They are nestin-positive
cells and once implanted into the gap region of the sciatic or tibial nerve, are able to enhance
the rate of nerve regeneration and the restoration of nerve function [141]. Wharton's jelly fish-
derived mesenchymal stem cells (WJMSCs) could be also a promising cell source for nerve
tissue engineering. It has been demonstrated that these cells can be differentiated into
Schwann-like cells and could be suitable Schwann-cell substitutes for nerve repair in clinical
applications [142]. A recent strategy for peripheral nerve regeneration is based on the use of
CD34(+) cells. Indeed, integration of CD34(+) cells in injured nerve significantly promotes
nerve regeneration [143]. However, limited migration and short survival of CD34(+) cells could
counteract this beneficial effect. One strategy could be the potentiation of CD34(+) cell
recruitment triggered by stromal cell-derived factor-1α (SDF-1α) [143]. This strategy based on
the over-expression of SDF-1α is providing interesting results in the peripheral neuropathy
treatment. It has been proposed that the expression of SDF-1α in the injured nerve exerts a
trophic effect by recruiting progenitor cells that promote nerve regeneration. Intravenous
administration of human amniotic fluid-derived mesenchymal stem cells facilitated neural
regeneration in a sciatic nerve crush injury model, when recruited by expression of SDF-1α in
muscle and nerve after nerve crush injury [144]. As mesenchymal stem cells, amniotic fluid-
derived mesenchymal stem cells have the ability to secrete neurotrophic factors that are able
to promote neuron survival. Their transplantation was able to regenerate the sciatic nerve after
crush injury by secretion of neurotrophic factors [145]. Interestingly, the stem cell mediated
effects could be enhanced by co-administration of several anti-inflammatory and anti-
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apoptotic factors, i.e. fermented soybean extracts or granulocyte-colony stimulating factor (G-
CSF) [146, 147].
In some cases, stem cell therapy does not provide optimal results. The multipotent capacity of
stem cells to differentiate into many cell types has led to successful therapy, but concerns
remain about the possible negative or harmful effects of the transplanted cultured cells [148].
Mahdi-Rogers et al. treated six patients with chronic acquired demyelinating neuropathy with
autologous peripheral blood stem cell transplantation (PBSCT) [149]. These patients were
refractory to other treatments; however, the authors reported serious adverse events and lack
of sustained response. There have been reports of inflammatory peripheral neuropathy or
polyneuropathy associated with chronic graft-versus-host disease (GVHD) [150], even if
pathogenesis has not been fully cleared. Doi et al. report a case of immune-mediated neuro‐
pathy after allogenic hematopoietic stem cell transplantation for Philadelphia-chromosome-
positive acute lymphoblastic leukemia [151].On the other hand, a case of peripheral
neuropathy induction was reported after autologous blood stem cell transplantation for
multiple myeloma [152]. Overall, these data indicate that before being suitable for clinical
applications, stem cell biology needs to be investigated further and in greater detail [153].
7. Conclusions
Neuropathic pain involves a complex network of mechanisms involving peripheral and central
nervous system. The peripheral nerve injury produces abnormal peripheral afferent inputs at
the spinal dorsal horn which leads to development of central sensitization and plastic changes
in supraspinal areas. The precise contribute of the different brain sites in neuropathic pain
development and maintenance is still far to be established. In particular the contribute of the
descending pain modulatory system including the PAG and the RVM is dual varying from
inhibitory to facilitatory. By this subject strategies able to shift the balance between facilitatory
versus inhibitory influences of the descending pathway may be useful to counteract neuro‐
pathic pain symptoms. Cannabinoids have been proved to stimulate the PAG-RVM inhibitory
pain control and inhibit neuropathic pain-related allodynia and hyperalgesia.
Neurons are not the only cell type involved in plastic changes at the base of pain hypersensi‐
tivity and activated microglia actively contribute to pain facilitation through a tight interaction
with neuron activity and the release of pain mediators. Novel strategies based on switching
off the microglia activation represents a possible therapeutic intervention to alleviate neuro‐
pathic pain.
Human mesenchymal stem cell transplantation has shown to reduce astrocytic and microglial
cell activation, mechanical allodynia and cellular and molecular pain mechanisms. The
therapeutic potentiality of stem cell to alleviate neuropathic pain appears encouraging,
however, its clinical application in peripheral neuropathy requires and deserves further
investigations.




Sabatino Maione, Enza Palazzo, Francesca Guida, Livio Luongo, Dario Siniscalco,
Ida Marabese, Francesco Rossi and Vito de Novellis
Department  of  Experimental  Medicine,  Division  of  Pharmacology,  Second University  of
Naples, Naples, Italy
References
[1] Wall, P. D, Devor, M, Inbal, R, Scadding, J. W, Schonfeld, D, Seltzer, Z, & Tomkie‐
wicz, M. M. Autotomy following peripheral nerve lesions: experimental anaesthesia
dolorosa. Pain (1979). , 7(2), 103-11.
[2] Bennett, G. J, & Xie, Y. K. A peripheral mononeuropathy in rat that produces disor‐
ders of pain sensation like those seen in man. Pain (1988). , 33(1), 87-107.
[3] Seltzer, Z, Dubner, R, & Shir, Y. A novel behavioral model of neuropathic pain disor‐
ders produced in rats by partial sciatic nerve injury. Pain (1990). , 43(2), 205-18.
[4] Kim, S. H, & Chung, J. M. (1992). An experimental model for peripheral neuropathy
produced by segmental spinal nerve ligation in the rat. Pain , 50, 355-363.
[5] Decosterd, I, & Woolf, C. J. Spared nerve injury: an animal model of persistent pe‐
ripheral neuropathic pain. Pain (2000). , 87(2), 149-58.
[6] Courteix, C, Bardin, M, Chantelauze, C, Lavarenne, J, & Eschalier, A. Study of the‐
sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain
(1994). , 57(2), 153-60.
[7] Higuera, E. S, & Luo, Z. D. A rat pain model of vincristine-induced neuropathy.
Methods Mol Med. (2004). , 99, 91-8.
[8] Joseph, E. K, Chen, X, Khasar, S. G, & Levine, J. D. Novel mechanism of enhanced
nociception in a model of AIDS therapy-induced painful peripheral neuropathy in
the rat. Pain (2004).
[9] Moalem, G, & Tracey, D. J. Immune and inflammatory mechanisms in neuropathic
pain. Brain Res Rev (2006). , 51(2), 240-64.
[10] Scholz, J, & Woolf, C. J. The neuropathic pain triad: neurons, immune cells and glia.
Nat Neurosci (2007). , 10, 1361-1368.
[11] Sommer, C, & Kress, M. Recent findings on how proinflammatory cytokines cause
pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuro‐
sci Lett. (2004).
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder88
[12] Pezet, S, & Mcmahon, S. B. Neurotrophins: mediators and modulators of pain. Annu
Rev Neurosci. (2006). , 29, 507-38.
[13] Hudson, L. J, Bevan, S, Wotherspoon, G, Gentry, C, Fox, A, & Winter, J. VR1 protein
expression increases in undamaged DRG neurons after partial nerve injury. Eur J
Neurosci (2001). , 13(11), 2105-14.
[14] Levine, J. D, & Alessandri-haber, N. TRP channels: targets for the relief of pain. Bio‐
chim Biophys Acta (2007). , 1772(8), 989-1003.
[15] Palazzo, E, Luongo, L, De Novellis, V, Berrino, L, Rossi, F, & Maione, S. Moving to‐
wards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain (2010).
[16] Palazzo, E, Guida, F, Gatta, L, Luongo, L, Boccella, S, Bellini, G, Marabese, I, De Nov‐
ellis, V, Rossi, F, & Maione, S. EP1 receptor within the ventrolateral periaqueductal
grey controls thermonociception and rostral ventromedial medulla cell activity in
healthy and neuropathic rat. Mol Pain (2011).
[17] Woolf, C. J, & Mannion, R. J. Neuropathic pain: Aetiology, symptoms, mechanisms,
and management. Lancet (1999). , 353(9168), 1959-64.
[18] Hong, S, Morrow, T. J, Paulson, P. E, Isom, L. L, & Wiley, J. W. Early painful diabetic
neuropathy is associated with differential changes in tetrodotoxin-sensitive and-re‐
sistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem
(2004). , 279(28), 29341-50.
[19] Hong, S, & Wiley, J. W. Early painful diabetic neuropathy is associated with differen‐
tial changes in the expression and function of vanilloid receptor 1. J Biol Chem
(2005). , 280(1), 618-27.
[20] Luo, Z. D, Chaplan, S. R, Higuera, E. S, Sorkin, L. S, Stauderman, K. A, Williams, M.
E, & Yaksh, T. L. Upregulation of dorsal root ganglion (alpha)2(delta) calcium chan‐
nel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci
(2001). , 21(6), 1868-75.
[21] Matthews, E. A, & Dickenson, A. H. Effects of spinally delivered N- and P-type volt‐
age-dependent calcium channel antagonists on dorsal horn neuronal responses in a
rat model of neuropathy. Pain (2001).
[22] Scholz, J. Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat
Neurosci (2007).
[23] Garden, G. A, & Moller, T. Microglia biology in health and disease. J Neuroimmune
Pharmacol (2006). , 1, 127-137.
[24] Trapp, B. D, Wujek, J. R, Criste, G. A, et al. Evidence for synaptic stripping by cortical
microglia. Glia (2007). , 55, 360-368.
[25] Coyle, D. E. Partial peripheral nerve injury leads to activation of astroglia and micro‐
glia which parallels the development of allodynic behavior. Glia (1998). , 23(1), 75-83.
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
89
[26] Jin, S. X, Zhuang, Z. Y, Woolf, C. J, & Ji, R. R. p38 mitogen-activated protein kinase is
activated after a spinal nerve ligation in spinal cord microglia and dorsal root gan‐
glion neurons and contributes to the generation of neuropathic pain. J Neurosci
(2003). , 23(10), 4017-22.
[27] Ledeboer, A, Sloane, E. M, Milligan, E. D, et al. Minocycline attenuates mechanical
allodynia and proinflammatory cytokine expression in rat models of pain facilitation.
Pain (2005).
[28] Luongo, L, Palazzo, E, Tambaro, S, et al. 1-(2',4'-dichlorophenyl)-6- methyl-N-cyclo‐
hexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3- carboxamide, a novel CB2 agonist,
alleviates neuropathic pain through functional microglial changes in mice. Neurobiol
Dis (2010). , 37, 177-85.
[29] Olechowski, C. J, Truong, J. J, & Kerr, B. J. Neuropathic pain behaviours in a chronic-
relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain (2009).
[30] Luongo, L, Sajic, M, Grist, J, Clark, A. K, Maione, S, & Malcangio, M. Spinal changes
associated with mechanical hypersensitivity in a model of Guillain-Barré syndrome.
Neurosci Lett (2008). , 437(2), 98-102.
[31] Stella, N. Endocannabinoid signaling in microglial cells. Neuropharmacology (2009).
Suppl , 1, 244-53.
[32] Medzhitov, R. Origin and physiological roles of inflammation. Nature (2008). ,
454(7203), 428-35.
[33] Romero-sandoval, A. Nutile-McMenemy N, DeLeo JA. Spinal microglial and peri‐
vascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensi‐
tivity without tolerance after peripheral nerve injury. Anesthesiology (2008). , 108(4),
722-734.
[34] Milligan, E. D, & Watkins, L. R. Pathological and protective roles of glia in chronic
pain. Nat Rev Neurosci (2009). , 10(1), 23-36.
[35] Abbadie, C, Bhangoo, S, De Koninck, Y, Malcangio, M, Melik- Parsadaniantz, S, &
White, F. A. Chemokines and pain mechanisms. Brain Res Rev (2009). , 60(1), 125-34.
[36] Lever, I. J, Bradbury, E. J, Cunningham, J. R, et al. Brain-derived neurotrophic factor
is released in the dorsal horn by distinctive patterns of afferent fiber stimulation. J
Neurosci (2001). , 21, 4469-4477.
[37] Svensson, C. I, Hua, X. Y, Protter, A. A, Powell, H. C, Yaksh, T. L, & Spinal, p. MAP
kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalge‐
sia. Neuroreport (2003a). , 14, 1153-1157.
[38] Taylor, D. L, Diemel, L. T, & Pocock, J. M. Activation of microglial group III metabo‐
tropic glutamate receptors protects neurons against microglial neurotoxicity. J Neu‐
rosci (2003). , 23(6), 2150-60.
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder90
[39] Biber, K, Laurie, D. J, Berthele, A, et al. Expression and signaling of group I metabo‐
tropic glutamate receptors in astrocytes and microglia. J Neurochem (1999). , 72(4),
1671-80.
[40] Bazan, J. F, Bacon, K. B, Hardiman, G, et al. A new class of membrane- bound chemo‐
kine with a CX3C motif. Nature (1997). , 385, 640-644.
[41] Lindia, J. A, Mcgowan, E, Jochnowitz, N, & Abbadie, C. Induction of CX3CL1 expres‐
sion in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neu‐
ropathic pain. J Pain (2005). , 6, 434-438.
[42] Clark, A. K, Yip, P. K, Grist, J, et al. Inhibition of spinal microglial cathepsin S for the
reversal of neuropathic pain. Proc Natl Acad Sci USA (2007). , 104, 10655-10660.
[43] Zhuang, ZY, Kawasaki, Y, Tan, PH, & Wen, . . Role of the CX3CR1/p38 MAPK path‐
way in spinal microglia for the development of neuropathic pain following nerve in‐
jury-induced cleavage of fractalkine. Brain Behav Immun 2007; 21: 642- 651
[44] Thacker, M. A, Clark, A. K, Bishop, T, et al. CCL2 is a key mediator of microglia acti‐
vation in neuropathic pain states. Eur J Pain (2009). , 13, 263-272.
[45] Abbadie, C, Lindia, J. A, Cumiskey, A. M, et al. Impaired neuropathic pain responses
in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA (2003). , 100,
7947-7952.
[46] Inoue, K, Tsuda, M, & Tozaki-saitoh, H. Modification of neuropathic pain sensation
through microglial ATP receptors. Purinergic Signal (2007). , 3, 311-316.
[47] Coull, J. A, Beggs, S, Boudreau, D, et al. BDNF from microglia causes the shift in neu‐
ronal anion gradient underlying neuropathic pain. Nature (2005). , 438, 1017-1021.
[48] Ulmann, L, Hatcher, J. P, Hughes, J. P, et al. Up-regulation of receptors in spinal mi‐
croglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J
Neurosci (2008). , 2X4.
[49] Clark, A. K, Wodarski, R, Guida, F, Sasso, O, & Malcangio, M. Cathepsin S release
from primary cultured microglia is regulated by the receptor. Glia (2010). , 2X7.
[50] Tozaki-saitoh, H, Tsuda, M, Miyata, H, Ueda, K, Kohsaka, S, & Inoue, K. P. Y12 re‐
ceptors in spinal microglia are required for neuropathic pain after peripheral nerve
injury. J Neurosci (2008). , 28(19), 4949-56.
[51] Kobayashi, K, Yamanaka, H, Fukuoka, T, Dai, Y, Obata, K, & Noguchi, K. P. Y12 re‐
ceptor upregulation in activated microglia is a gateway of signaling and neuropathic
pain. J Neurosci (2008). , 38.
[52] Haynes, S. E, Hollopeter, G, Yang, G, et al. The 2Y12 receptor regulates microglial ac‐
tivation by extracellular nucleotides. Nat Neurosci (2006).
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
91
[53] Orr, A. G, Orr, A. L, Li, X. J, Gross, R. E, Traynelis, S. F, & Adenosine, A. A) receptor
mediates microglial process retraction. Nat Neurosci (2009). , 12(7), 872-8.
[54] Pertovaara, A. Plasticity in descending pain modulatory systems. Prog Brain Res
(2000). , 129, 231-42.
[55] Porreca, F, Ossipov, M. H, & Gebhart, G. F. Chronic pain and medullary descending
facilitation. Trends Neurosci. (2002). , 25(6), 319-25.
[56] Ossipov, M. H, & Porreca, F. Chapter 14 Descending excitatory systems. Handb Clin
Neurol. (2006). , 81, 193-210.
[57] Reynolds, D. V. Surgery in the rat during electrical analgesia induced by focal brain
stimulation. Science (1969). Apr 25;, 164(3878), 444-5.
[58] Jones, S. L, & Gebhart, G. F. Inhibition of spinal nociceptive transmission from the
midbrain, pons and medulla in the rat: activation of descending inhibition by mor‐
phine, glutamate and electrical stimulation. Brain Res (1988).
[59] Fields, H. L, Bry, J, Hentall, I, & Zorman, G. The activity of neurons in the rostral me‐
dulla of the rat during withdrawal from noxious heat. J Neurosci. (1983).
[60] Fields, H. L, Basbaum, A. I, & Heinricher, M. M. (2006). Central nervous system
mechanisms of pain modulation. In Mcmahon, SB and Kolzenburg M (Eds), Wall
and Melzack’s textbook of pain, 5th edn. Elsevier Location, China, , 125-142.
[61] Gebhart, G. F. Descending modulation of pain. Neurosci Biobehav Rev. (2004). Jan;,
27(8), 729-37.
[62] Vanegas, H, & Schaible, H. G. Descending control of persistent pain: inhibitory or fa‐
cilitatory? Brain Res Brain Res Rev. (2004). , 46(3), 295-309.
[63] Gonçalves, L, Almeida, A, & Pertovaara, A. Pronociceptive changes in response
properties of rostroventromedial medullary neurons in a rat model of peripheral
neuropathy. Eur J Neurosci (2007). , 26(8), 2188-95.
[64] Kovelowski, C. J, Ossipov, M. H, Sun, H, Lai, J, Malan, T. P, & Porreca, F. Supraspi‐
nal cholecystokinin may drive tonic descending facilitation mechanisms to maintain
neuropathic pain in the rat. Pain (2000). , 87(3), 265-73.
[65] Porreca, F, Burgess, S. E, Gardell, L. R, & Vanderah, T. W. Malan TP Jr, Ossipov MH,
Lappi DA, Lai J. Inhibition of neuropathic pain by selective ablation of brainstem me‐
dullary cells expressing the mu-opioid receptor. J Neurosci. (2001). , 21(14), 5281-8.
[66] Carlson, J. D, Maire, J. J, Martenson, M. E, & Heinricher, M. M. Sensitization of pain-
modulating neurons in the rostral ventromedial medulla after peripheral nerve in‐
jury. J Neurosci (2007). , 27(48), 13222-31.
[67] Palazzo, E, Luongo, L, Bellini, G, Guida, F, Marabese, I, Boccella, S, Rossi, F, Maione,
S, & De Novellis, V. Changes in cannabinoid receptor subtype 1 activity and interac‐
tion with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-ros‐
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder92
tral ventromedial medulla pathway in a rodent neuropathic pain model. CNS Neurol
Disord Drug Targets. (2012). , 2012(11), 148-61.
[68] Suzuki, R, Rygh, L. J, & Dickenson, A. H. Bad news from the brain: descending 5-HT
pathways that control spinal pain processing. Trends Pharmacol. Sci. (2004). , 25,
613-617.
[69] Millecamps, M, Centeno, M. V, Berra, H. H, Rudick, C. N, Lavarello, S, & Tkatch, T.
Apkarian AV. D-cycloserine reduces neuropathic pain behavior through limbic
NMDA-mediated circuitry. Pain (2007).
[70] Tracey, I, & Mantyh, P. W. The cerebral signature for pain perception and its modu‐
lation. Neuron. (2007). , 55(3), 377-91.
[71] Campbell, J. N, & Meyer, R. A. Mechanisms of neuropathic pain. Neuron (2006). ,
52(1), 77-92.
[72] Petrosino, S, Palazzo, E, De Novellis, V, Bisogno, T, Rossi, F, & Maione, S. Di Marzo
V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats.
Neuropharmacology (2007). , 52(2), 415-22.
[73] Palazzo, E, De Novellis, V, Petrosino, S, Marabese, I, Vita, D, & Giordano, C. Di Mar‐
zo V, Mangoni GS, Rossi F, Maione S. Neuropathic pain and the endocannabinoid
system in the dorsal raphe: pharmacological treatment and interactions with the se‐
rotonergic system. Eur J Neurosci. (2006). , 24(7), 2011-20.
[74] Floresco, S. B, & Tse, M. T. Dopaminergic regulation of inhibitory and excitatory
transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci.
(2007). Feb 21;, 27(8), 2045-57.
[75] De Novellis, V, Vita, D, Gatta, L, Luongo, L, Bellini, G, De Chiaro, M, Marabese, I,
Siniscalco, D, Boccella, S, & Piscitelli, F. Di Marzo V, Palazzo E, Rossi F, Maione S.
The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide
hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex
of neuropathic rats. Mol Pain (2011). , 17, 7-7.
[76] Fu, Y, & Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor func‐
tions in the amygdala in pain-related synaptic facilitation and behavior. J Neurosci.
20089;, 28(15), 3861-76.
[77] Neugebauer, V, Galhardo, V, Maione, S, & Mackey, S. C. Forebrain pain mechanisms.
Brain Res Rev (2009). , 60(1), 226-42.
[78] Ji, G, & Neugebauer, V. Hemispheric lateralization of pain processing by amygdala
neurons. J Neurophysiol (2009). , 102(4), 2253-64.
[79] Metz, A. E, Yau, H. J, Centeno, M. V, Apkarian, A. V, & Martina, M. Morphological
and functional reorganization of rat medial prefrontal cortex in neuropathic pain.
Proc Natl Acad Sci U S A (2009). , 106(7), 2423-8.
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
93
[80] Giordano, C, Cristino, L, Luongo, L, Siniscalco, D, Petrosino, S, Piscitelli, F, Marab‐
ese, I, Gatta, L, Rossi, F, Imperatore, R, Palazzo, E, & De Novellis, V. Di Marzo V,
Maione S. Cereb Cortex (2011). in press
[81] Matsuda, L. A, Lolait, S. J, Brownstein, M. J, Young, A. C, & Bonner, T. I. Structure of
a cannabinoid receptor and functional expression of the cloned cDNA. Nature
(1990). , 346, 561-564.
[82] Herkenham, M, Lynn, A. B, Johnson, M. R, Melvin, L. S, De Costa, B. R, & Rice, K. C.
Characterization and localization of cannabinoid receptors inrat brain: a quantitative
in vitro autoradiographic study J Neurosci(1991). , 1, 563-583.
[83] Devane, W. A, Hanus, L, Breuer, A, et al. Isolation and structure of a brain constitu‐
ent that binds to the cannabinoid receptor Science (1992). , 258, 1946-1949.
[84] Fride, E, Bregman, T, & Kirkham, T. C. Endocannabinoids and food intake: newborn
suckling and appetite regulation in adulthood. Exp Biol Med (2005). Review., 230(4),
225-34.
[85] Guindon, J, & Hohmann, A. G. The endocannabinoid system and pain.CNS Neurol
Disord Drug Targets. (2009). Review., 8(6), 403-21.
[86] Howlett, A. C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol (2005). , 168,
53-79.
[87] Bushlin, I, Rozenfeld, R, & Devi, L. A. Cannabinoid-opioid interactions during neu‐
ropathic pain and analgesia. Curr Opin Pharmacol. (2010). , 10(1), 80-6.
[88] Miller, L. K, & Devi, L. A. The highs and lows of cannabinoid receptor expression in
disease: mechanisms and their therapeutic implications. Pharmacol Rev. (2011). ,
63(3), 461-70.
[89] Van Sickle, M. D, Duncan, M, Kingsley, P. J, Mouihate, A, Urbani, P, Mackie, K, Stel‐
la, N, Makriyannis, A, Piomelli, D, Davison, J. S, & Marnett, L. J. Di Marzo V, Pittman
QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem
cannabinoid CB2 receptors Science (2005). , 310, 329-332.
[90] Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E,
Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT,
Wise A, Brown AJ
[91] Sharir, H. and Abood, M.E. Pharmacological characterization of GPR55, a putative
cannabinoid receptor Pharmacol. Ther 2010;126(3):301–313
[92] Zygmunt, P. M, Petersson, J, Andersson, D. A, Chuang, H, & Sorgard, M. Di Marzo,
V., Julius, D., and Hogestatt, E.D. Vanilloid receptors on sensory nerves mediate the
vasodilator action of anandamide Nature (1999). , 400(6743), 452-457.
[93] Sullivan, O. S.E. Cannabinoids go nuclear: evidence for activation of peroxisome pro‐
liferator-activated receptors Br. J. Pharmacol. (2007). , 152(5), 576-582.
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder94
[94] Stella, N, Schweitzer, P, & Piomelli, D. A second endogenous cannabinoid that mod‐
ulates long-term potentiation Nature (1997). , 388, 773-778.
[95] Beltramo, M, & Piomelli, D. Carrier-mediated transport and enzymatic hydrolysis of
the endogenous cannabinoid 2-arachidonylglycerol Neuropharmacology (2000). , 11,
1231-1235.
[96] Di Marzo VTargeting the endocannabinoid system: to enhance or reduce? Nat Rev
Drug Discov (2008). , 7, 438-455.
[97] Kozak, K. R, Rowlinson, S. W, & Marnett, L. J. Oxygenation of the endocannabinoid,
2 arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2 J Biol Chem
(2000). , 275, 33744-33749.
[98] Blankman, J. L, Simon, G. M, & Cravatt, B. F. A comprehensive profile of brain en‐
zymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol Chem Biol
(2007). , 14, 1347-1356.
[99] Dixon, W. E. The pharmacology of cannabis indica Br Med J (1899). , 2, 1354-7.
[100] Bicher, H. I, & Mechoulam, R. Pharmacological effects of two active constituents of
marihuana Arch Int Pharmacodyn Ther 196 ;, 172, 24-31.
[101] Kosersky, D. S, Dewey, W. L, & Harris, L. S. Antipyretic, analgesic and anti-infl am‐
matory effects of delta 9-tetrahydrocannabinol in the rat Eur J Pharmacol (1973). , 24,
1-7.
[102] Costa, B, Colleoni, M, Conti, S, Trovato, A. E, Bianchi, M, Sotgiu, M. L, & Giagnoni,
G. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both
hyperalgesia and production of pronociceptive mediators in a rat model of neuro‐
pathic pain Br J Pharmacol (2004). , 141(1), 4-8.
[103] Ossipov, M. H, Lopez, Y, Nichols, M. L, Bian, D, & Porreca, F. The loss of antinoci‐
ceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by
reducing spinal afferent drive.Neurosci Lett (1995). , 199(2), 87-90.
[104] Rashid, M. H, Inoue, M, Toda, K, & Ueda, H. Loss of peripheral morphine analgesia
contributes to the reduced effectiveness of systemic morphine in neuropathic pain J
Pharmacol Exp Ther. (2004). , 309(1), 380-7.
[105] Guindon, J, & Beaulieu, P. Antihyperalgesic effects of local injections of anandamide,
ibuprofen, rofecoxib and their combinations in a model of neuropathic pain Neuro‐
pharmacology (2006). , 50, 814-823.
[106] Helyes, Z, Németh, J, Thán, M, Bölcskei, K, Pintér, E, & Szolcsányi, J. Inhibitory effect
of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and
neuropathic hyperalgesia in the rat Life Sci (2003). , 73, 2345-2353.
[107] Costa, B, Siniscalco, D, Trovato, A. E, Comelli, F, Sotgiu, M. L, Colleoni, M, Maione,
S, Rossi, F, & Giagnoni, G. AM404, an inhibitor of anandamide uptake, prevents pain
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
95
behaviour and modulates cytokine and apoptotic pathways in a rat model of neuro‐
pathic pain Br J Pharmacol (2006). , 148, 1022-1032.
[108] Martin, W. J, Coffin, P. O, Attias, E, Balinsky, M, Tsou, K, & Walker, J. M. Anatomical
basis for cannabinoid-induced antinociception as revealed by intracerebral microin‐
jections Brain Res. (1999).
[109] Maione, S, Bisogno, T, De Novellis, V, Palazzo, E, Cristino, L, Valenti, M, Petrosino,
S, Guglielmotti, V, & Rossi, F. Di Marzo V. Elevation of endocannabinoid levels in
the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydro‐
lase affects descending nociceptive pathways via both CB1 and TRPV1 receptors. J
Pharmacol Exp Ther (2006). , 316, 969-982.
[110] Racz, I, Nadal, X, Alferink, J, Baños, J. E, Rehnelt, J, Martín, M, Pintado, B, Gutierrez-
adan, A, Sanguino, E, Manzanares, J, Zimmer, A, & Maldonado, R. Crucial role of
CB(2) cannabinoid receptor in the regulation of central immune responses during
neuropathic pain. J Neurosci (2008a). , 28(46), 12125-35.
[111] Racz, I, Nadal, X, Alferink, J, Baños, J. E, Rehnelt, J, Martín, M, Pintado, B, Gutierrez-
adan, A, Sanguino, E, Bellora, N, Manzanares, J, & Zimmer, A. Maldonado R Inter‐
feron-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during
neuropathic pain.J Neurosci. (2008B). , 28(46), 12136-45.
[112] Anand, P, Whiteside, G, Fowler, C. J, & Hohmann, A. G. Targeting CB2 receptors
and the endocannabinoid system for the treatment of pain Brain Res Rev (2009). ,
60(1), 255-66.
[113] Hampson, R. E, & Deadwyler, S. A. Cannabinoids, hippocampal function and memo‐
ry. Life Sci (1999). Review
[114] Pertwee, R. G. The central neuropharmacology of psychotropic cannabinoids. Phar‐
macol Ther. (1988). Review
[115] Maccarrone, M, & Wenger, T. Effects of cannabinoids on hypothalamic and repro‐
ductive function. Handb Exp Pharmacol (2005).
[116] Ibrahim, M. M, Lai, J, Vanderah, T. W, Makriyannis, A, & Porreca, F. CB2 cannabi‐
noid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharma‐
col (2003). Review., 3(1), 62-7.
[117] Maione, S, Piscitelli, F, Gatta, L, Vita, D, De Petrocellis, L, Palazzo, E, & De Novellis,
V. Di Marzo V. Non-psychoactive cannabinoids modulate the descending pathway
of antinociception in anaesthetized rats through several mechanisms of action Br J
Pharmacol (2011). , 162(3), 584-96.
[118] Costa, B, Trovato, A. E, Comelli, F, Giagnoni, G, & Colleoni, M. The non-psychoac‐
tive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat
chronic inflammatory and neuropathic pain Eur J Pharmacol (2007).
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder96
[119] Reid, A. J, Sun, M, Wiberg, M, Downes, S, Terenghi, G, & Kingham, P. J. Nerve repair
with adipose-derived stem cells protects dorsal root ganglia neurons from apoptosis.
Neuroscience. (2011). , 199, 515-522.
[120] Siniscalco, D, Rossi, F, & Maione, S. Stem cell therapy for neuropathic pain treatment.
J Stem Cells and Regenerative Medicine (2008). vol III (1).
[121] Siniscalco, D, Bradstreet, J. J, & Antonucci, N. Cell therapies for Autism Spectrum
Disorders. Autism Spectrum Disorders: New Research. (2012). Edited by : Nova Sci‐
ence Publishers, Hauppauge, NY.
[122] Dadon-nachum, M, Sadan, O, Srugo, I, Melamed, E, & Offen, D. Differentiated mes‐
enchymal stem cells for sciatic nerve injury. Stem Cell Rev (2011a). , 7(3), 664-71.
[123] Martínez de Albornoz PDelgado PJ, Forriol F, Maffulli N. Non-surgical therapies for
peripheral nerve injury. Br Med Bull (2011). , 100, 73-100.
[124] Dadon-nachum, M, Melamed, E, & Offen, D. Stem cells treatment for sciatic nerve in‐
jury. Expert Opin Biol Ther (2011b). , 11(12), 1591-1597.
[125] Azizi, S. A, Stokes, D, & Augelli, B. J. DiGirolamo C, Prockop DJ. Engraftment and
migration of human bone marrow stromal cells implanted in the brains of albino
rats- similarities to astrocyte grafts. Proc. Natl. Acad. Sci USA(1998). , 95, 3908-3913.
[126] Marconi, S, Castiglione, G, Turano, E, Bissolotti, G, Angiari, S, Farinazzo, A, Constan‐
tin, G, Bedogni, G, Bedogni, A, & Bonetti, B. Human adipose-derived mesenchymal
stem cells systemically injected promote peripheral nerve regeneration in the mouse
model of sciatic crush. Tissue Eng Part A. (2012).
[127] Siniscalco, D. Transplantation of human mesenchymal stem cells in the study of neu‐
ropathic pain. Methods Mol Biol. (2010). , 617, 337-345.
[128] Dezawa, M. Future views and challenges to the peripheral nerve regeneration by cell
based therapy. Rinsho Shinkeigaku (2005). , 45(11), 877-879.
[129] Frattini, F. Pereira Lopes FR, Almeida FM, Rodrigues RF, Boldrini LC, Tomaz MA,
Baptista AF, Melo PA, Martinez AM. Mesenchymal Stem Cells in a Polycaprolactone
Conduit Promote Sciatic Nerve Regeneration and Sensory Neuron Survival After
Nerve Injury. Tissue Eng Part A. (2012). in press.
[130] Malandrini, A, Eramo, D, Palmeri, C, Gaudiano, S, Gambelli, C, Sicurelli, S, Berti, F,
Formichi, G, Kuqo, P, Dotti, A, & Federico, M. T. A. Peripheral neuropathy in late-
onset Krabbe disease: report of three cases. Neurol Sci. (2012). in press.
[131] Siddiqi, Z. A, Sanders, D. B, & Massey, J. M. Peripheral neuropathy in Krabbe dis‐
ease: effect of hematopoietic stem cell transplantation. Neurology. (2006). , 67(2),
268-272.
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
97
[132] Kim, H, Kim, J. J, & Yoon, Y. S. Emerging therapy for diabetic neuropathy: cell thera‐
py targeting vessels and nerves. Endocr Metab Immune Disord Drug Targets.
(2012). , 12(2), 168-178.
[133] Naruse, K, Sato, J, Funakubo, M, Hata, M, Nakamura, N, Kobayashi, Y, Kamiya, H,
Shibata, T, Kondo, M, Himeno, T, Matsubara, T, Oiso, Y, & Nakamura, J. Transplan‐
tation of bone marrow-derived mononuclear cells improves mechanical hyperalge‐
sia, cold allodynia and nerve function in diabetic neuropathy. PLoS One (2011).
e27458.
[134] Ebben, J. D, Zorniak, M, Clark, P. A, & Kuo, J. S. Introduction to induced pluripotent
stem cells: advancing the potential for personalized medicine. World Neurosurg
(2011).
[135] Uemura, T, Takamatsu, K, Ikeda, M, Okada, M, Kazuki, K, Ikada, Y, & Nakamura, H.
Transplantation of induced pluripotent stem cell-derived neurospheres for peripher‐
al nerve repair. Biochem Biophys Res Commun (2012). , 419(1), 130-135.
[136] Walsh, S. K, Kumar, R, Grochmal, J. K, Kemp, S. W, Forden, J, & Midha, R. Fate of
stem cell transplants in peripheral nerves. Stem Cell Res. (2012). , 8(2), 226-238.
[137] Ren, Z, Wang, Y, Peng, J, Zhao, Q, & Lu, S. Role of stem cells in the regeneration and
repair of peripheral nerves. Rev Neurosci. (2012). , 23(2), 135-143.
[138] Walsh, S, Biernaskie, J, Kemp, S. W, & Midha, R. Supplementation of acellular nerve
grafts with skin derived precursor cells promotes peripheral nerve regeneration.
Neuroscience (2009). , 164(3), 1097-1107.
[139] Amoh, Y, & Hoffman, R. M. Isolation and culture of hair follicle pluripotent stem
(hfPS) cells and their use for nerve and spinal cord regeneration. Methods Mol Biol.
(2010). , 585, 401-420.
[140] Amoh, Y, Aki, R, Hamada, Y, Niiyama, S, Eshima, K, Kawahara, K, Sato, Y, Tani, Y,
Hoffman, R. M, & Katsuoka, K. Nestin-positive hair follicle pluripotent stem cells can
promote regeneration of impinged peripheral nerve injury. J Dermatol. (2012). , 39(1),
33-38.
[141] Hoffman, R. M. The potential of nestin-expressing hair follicle stem cells in regenera‐
tive medicine. Expert Opin Biol Ther. (2007). , 7(3), 289-291.
[142] Peng, J, Wang, Y, Zhang, L, Zhao, B, Zhao, Z, Chen, J, Guo, Q, Liu, S, Sui, X, Xu, W,
& Lu, S. Human umbilical cord Wharton’s jelly-derived mesenchymal stem cells dif‐
ferentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro.
Brain Res Bull. (2011). , 84(3), 235-243.
[143] Sheu, M. L, Cheng, F. C, Su, H. L, Chen, Y. J, Chen, C. J, Chiang, C. M, Chiu, W. T,
Sheehan, J, & Pan, H. C. Recruitment by SDF-1α of CD34-positive cells involved in
sciatic nerve regeneration. J Neurosurg (2012). , 116(2), 432-444.
Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder98
[144] Yang, D. Y, Sheu, M. L, Su, H. L, Cheng, F. C, Chen, Y. J, Chen, C. J, Chiu, W. T, Yiin,
J. J, Sheehan, J, & Pan, H. C. Dual regeneration of muscle and nerve by intravenous
administration of human amniotic fluid-derived mesenchymal stem cells regulated
by stromal cell-derived factor-1α in a sciatic nerve injury model. J Neurosurg.
(2012). , 116(6), 1357-1367.
[145] Pan, H. C, Cheng, F. C, Chen, C. J, Lai, S. Z, Lee, C. W, Yang, D. Y, Chang, M. H, &
Ho, S. P. Post-injury regeneration in rat sciatic nerve facilitated by neurotrophic fac‐
tors secreted by amniotic fluid mesenchymal stem cells. J Clin Neurosci. (2007). ,
14(11), 1089-1098.
[146] Pan, H. C, Yang, D. Y, Ho, S. P, Sheu, M. L, Chen, C. J, Hwang, S. M, Chang, M. H, &
Cheng, F. C. Escalated regeneration in sciatic nerve crush injury by the combined
therapy of human amniotic fluid mesenchymal stem cells and fermented soybean ex‐
tracts, Natto. J Biomed Sci. (2009). a..
[147] Pan, H. C, Chen, C. J, Cheng, F. C, Ho, S. P, Liu, M. J, Hwang, S. M, Chang, M. H, &
Wang, Y. C. Combination of G-CSF administration and human amniotic fluid mesen‐
chymal stem cell transplantation promotes peripheral nerve regeneration. Neuro‐
chem Res. (2009). b., 34(3), 518-527.
[148] Mohseny AB Hogendoorn PCConcise review: Mesenchymal tumors when stem cells
go mad. Stem Cells. (2011). , 29, 397-403.
[149] Mahdi-rogers, M, Kazmi, M, Ferner, R, Hughes, R. A, Renaud, S, Steck, A. J, Fuhr, P,
Halter, J, Gratwohl, A, & Tyndall, A. Autologous peripheral blood stem cell trans‐
plantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst
(2009). , 14(2), 118-124.
[150] Amato, A. A, Barohn, R. J, Sahenk, Z, Tutschka, P. J, & Mendell, J. R. Polyneuropathy
complicating bone marrow and solid organ transplantation. Neurology (1993). , 43,
1513-1518.
[151] Doi, Y, Sugahara, H, Yamamoto, K, Uji-ie, H, Kakimoto, T, & Sakoda, H. Immune-
mediated peripheral neuropathy occurring simultaneously with recurrent graft-ver‐
sus-host disease after allogenic hematopoietic stem cell transplantation. Leuk Res.
(2012). e, 63-65.
[152] Boiron, J. M, Ellie, E, Vital, A, Marit, G, Rème, T, Vital, C, Broustet, A, & Reiffers, J.
Peripheral neuropathy after autologous blood stem cell transplantation for multiple
myeloma. Leukemia (1994). , 8(2), 322-326.
[153] Siniscalco, D, Giordano, A, & Galderisi, U. Novel insights in basic and applied stem
cell therapy. J Cell Physiol (2012). , 227(5), 2283-2286.
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies
http://dx.doi.org/10.5772/55276
99

